-
1 Comment
Med BioGene Inc is currently in a long term uptrend where the price is trading 95.5% above its 200 day moving average.
From a valuation standpoint, the stock is 100.0% cheaper than other stocks from the Healthcare sector with a price to sales ratio of 0.0.
Med BioGene Inc's total revenue sank by nan% to $0 since the same quarter in the previous year.
Its net income has dropped by 177.0% to $-9K since the same quarter in the previous year.
Finally, its free cash flow grew by 779.3% to $83K since the same quarter in the previous year.
Based on the above factors, Med BioGene Inc gets an overall score of 3/5.
| ISIN | None |
|---|---|
| Industry | Diagnostics & Research |
| Sector | Healthcare |
| CurrencyCode | CAD |
| Exchange | V |
| Market Cap | 86K |
|---|---|
| PE Ratio | None |
| Target Price | None |
| Beta | 0.02 |
| Dividend Yield | 0.0% |
Many Bright Ideas Technologies Inc. does not have significant operations. Previously, the company was engaged in the life science business with a focus on the development and commercialization of genomic-based tests for non-small-cell lung cancer. It focuses on the commercialization of technologies in various industrial sectors. The company was formerly known as Med BioGene Inc. and changed its name to Many Bright Ideas Technologies Inc. in June 2022. Many Bright Ideas Technologies Inc. was incorporated in 2006 and is headquartered in Vancouver, Canada.
Learn MoreHere's how to backtest a trading strategy or backtest a portfolio for MBI-H.V using our backtest tool. PyInvesting provides the backtesting software for you to backtest your investment strategy. Our backtest software is written using Python code and allows you to backtest stock, backtest etf, backtest options, backtest crypto and backtest forex online. Our backtesting Python framework is highly robust and gives you a realistic simulation of how your strategy would have performed in the past using backtest data.
© PyInvesting 2024
